Francesca Gay, MD, PhD, is currently an Associate Professor of Hematology at the Myeloma Unit in the Division of Hematology at the University of Turin, Turin, Italy, having previously worked as a Hematologist at the Azienda Ospedaliera Città della Salute e della Scienza di Torino, Turin, Italy.
Dr Gay completed her medical degree in 2004 and her fellowship in hematology in 2008, both from the University of Turin. In 2014, Dr Gay obtained a PhD in Medicine and Experimental Therapy and has been a member of the young European Myeloma Network (EMN) board since its formation in 2019.
Speaking on treating myeloma and associated disorders
Dr Gay’s research is focused on the treatment of multiple myeloma and its associated diseases. Dr Gay has previously worked on many cutting-edge clinical trials and is currently heavily involved in research investigating prognostic factors, such as measurable residual disease (MRD), in multiple myeloma.